Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Journal of Diabetes Science and Technology|September 2, 2011
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace studyAndreas Pfützner, Markolf Hanefeld, Lida A Dekordi, et al.
Advances in Therapy|August 22, 2014
Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trialsMarkolf Hanefeld, Rachele Berria, Jay Lin, et al.
Archives of Internal Medicine|October 27, 2004
Postprandial glucose regulation and diabetic complicationsAntonio Ceriello, Markolf Hanefeld, Lawrence Leiter, et al.
Atherosclerosis|April 1, 2008
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT studyWolfgang Leonhardt, Andreas Pfützner, Jürgen Müller, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|August 29, 2006
Postprandial hyperglycaemia and cardiovascular complications of diabetes: an updateAntonio Ceriello, Jamie Davidson, Markolf Hanefeld, et al.
Journal of the American College of Cardiology|January 24, 2007
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT StudyMarkolf Hanefeld, Nikolaus Marx, Andreas Pfützner, et al.
Diabetes, Obesity & Metabolism|June 20, 2020
Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry studyKarim Sultan Haider, Ahmad Haider, Farid Saad, et al.
Diabetes Technology & Therapeutics|May 23, 2009
The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profilesAndreas Thomas, Martin Schönauer, Frank Achermann, et al.
Diabetologia|April 29, 2014
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, Richard E Gilbert, Johannes F E Mann, et al.
Diabetes Care|December 29, 2006
The effect of glucose variability on the risk of microvascular complications in type 1 diabetesLouis Monnier, Claude Colette, Lawrence Leiter, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Journal of Diabetes Science and Technology|September 2, 2011
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace studyAndreas Pfützner, Markolf Hanefeld, Lida A Dekordi, et al.
Advances in Therapy|August 22, 2014
Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trialsMarkolf Hanefeld, Rachele Berria, Jay Lin, et al.
Archives of Internal Medicine|October 27, 2004
Postprandial glucose regulation and diabetic complicationsAntonio Ceriello, Markolf Hanefeld, Lawrence Leiter, et al.
Atherosclerosis|April 1, 2008
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT studyWolfgang Leonhardt, Andreas Pfützner, Jürgen Müller, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|August 29, 2006
Postprandial hyperglycaemia and cardiovascular complications of diabetes: an updateAntonio Ceriello, Jamie Davidson, Markolf Hanefeld, et al.
Journal of the American College of Cardiology|January 24, 2007
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT StudyMarkolf Hanefeld, Nikolaus Marx, Andreas Pfützner, et al.
Diabetes, Obesity & Metabolism|June 20, 2020
Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry studyKarim Sultan Haider, Ahmad Haider, Farid Saad, et al.
Diabetes Technology & Therapeutics|May 23, 2009
The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profilesAndreas Thomas, Martin Schönauer, Frank Achermann, et al.
Diabetologia|April 29, 2014
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, Richard E Gilbert, Johannes F E Mann, et al.
Diabetes Care|December 29, 2006
The effect of glucose variability on the risk of microvascular complications in type 1 diabetesLouis Monnier, Claude Colette, Lawrence Leiter, et al.
Pageof 13